Search

Your search keyword '"Diletto, B"' showing total 154 results
Start Over Author "Diletto, B"
154 results on '"Diletto, B"'

2. Reduced-dose craniospinal irradiation is feasible for standard-risk adult medulloblastoma patients

Author

Massimino, M, Sunyach, M, Barretta, F, Gandola, L, Garegnani, A, Pecori, E, Spreafico, F, Bonneville-Levard, A, Meyronet, D, Mottolese, C, Boschetti, L, Biassoni, V, Schiavello, E, Giussani, C, Carrabba, G, Diletto, B, Pallotti, F, Stefini, R, Ferrari, A, Terenziani, M, Casanova, M, Luksch, R, Meazza, C, Podda, M, Chiaravalli, S, Puma, N, Bergamaschi, L, Morosi, C, Calareso, G, Giangaspero, F, Antonelli, M, Buttarelli, F, Frappaz, D, Massimino M., Sunyach M. P., Barretta F., Gandola L., Garegnani A., Pecori E., Spreafico F., Bonneville-Levard A., Meyronet D., Mottolese C., Boschetti L., Biassoni V., Schiavello E., Giussani C., Carrabba G., Diletto B., Pallotti F., Stefini R., Ferrari A., Terenziani M., Casanova M., Luksch R., Meazza C., Podda M., Chiaravalli S., Puma N., Bergamaschi L., Morosi C., Calareso G., Giangaspero F., Antonelli M., Buttarelli F. R., Frappaz D., Massimino, M, Sunyach, M, Barretta, F, Gandola, L, Garegnani, A, Pecori, E, Spreafico, F, Bonneville-Levard, A, Meyronet, D, Mottolese, C, Boschetti, L, Biassoni, V, Schiavello, E, Giussani, C, Carrabba, G, Diletto, B, Pallotti, F, Stefini, R, Ferrari, A, Terenziani, M, Casanova, M, Luksch, R, Meazza, C, Podda, M, Chiaravalli, S, Puma, N, Bergamaschi, L, Morosi, C, Calareso, G, Giangaspero, F, Antonelli, M, Buttarelli, F, Frappaz, D, Massimino M., Sunyach M. P., Barretta F., Gandola L., Garegnani A., Pecori E., Spreafico F., Bonneville-Levard A., Meyronet D., Mottolese C., Boschetti L., Biassoni V., Schiavello E., Giussani C., Carrabba G., Diletto B., Pallotti F., Stefini R., Ferrari A., Terenziani M., Casanova M., Luksch R., Meazza C., Podda M., Chiaravalli S., Puma N., Bergamaschi L., Morosi C., Calareso G., Giangaspero F., Antonelli M., Buttarelli F. R., and Frappaz D.

Abstract

Introduction: Medulloblastoma is the most common malignant brain tumor in children, but accounts for only 1% of brain cancers in adults. For standard-risk pediatric medulloblastoma, current therapy includes craniospinal irradiation (CSI) at reduced doses (23.4 Gy) associated with chemotherapy. Whereas most same-stage adult patients are still given CSI at 36 Gy, with or without chemotherapy, we report here on our use of reduced-dose CSI associated with chemotherapy for older patients. Methods: We gathered non-metastatic patients over 18 years old (median age 28 years, range 18–48) with minimal or no residual disease after surgery, no negative histological subtypes, treated between 1996–2018 at the Centre Léon Bérard (Lyon) and the INT (Milano). A series of 54 children with similar tumors treated in Milano was used for comparison. Results: Forty-four adults were considered (median follow-up 101 months): 36 had 23.4 Gy of CSI, and 8 had 30.6 Gy, plus a boost to the posterior fossa/tumor bed; 43 had chemotherapy as all 54 children, who had a median 83-month follow-up. The PFS and OS were 82.2 ± 6.1% and 89 ± 5.2% at 5 years, and 78.5 ± 6.9% and 75.2 ± 7.8% at ten, not significantly different from those of the children. CSI doses higher than 23.4 Gy did not influence PFS. Female adult patients tended to have a better outcome than males. Conclusion: The results obtained in our combined series are comparable with, or even better than those obtained after high CSI doses, underscoring the need to reconsider this treatment in adults.

Published
2020

7. PV-0364 Pulmonary function after high dose chemotherapy + total lung irradiation for pediatric Ewing sarcoma

Author

Diletto, B., primary, Pecori, E., additional, Puma, N., additional, Alessandro, O., additional, Meroni, S., additional, Podda, M., additional, Busia, A., additional, Allegri, F., additional, Ogliari, A.C., additional, Materazzo, C., additional, Boffi, R., additional, Pignoli, E., additional, Luksch, R., additional, and Gandola, L., additional

Published
2019
Full Text
View/download PDF

8. 50. Retrospective study of late radiation damages after focal radiotherapy for childhood brain tumors

Author

Meroni, S., primary, Cavatorta, C., additional, Lecchi, M., additional, Montin, E., additional, Oprandi, C., additional, Pecori, E., additional, Spreafico, F., additional, Diletto, B., additional, Biassoni, V., additional, Schiavello, E., additional, Arrigoni, F., additional, Poggi, G., additional, Massimino, M., additional, Mainardi, L., additional, Verderio, P., additional, Pignoli, E., additional, and Gandola, L., additional

Published
2018
Full Text
View/download PDF

10. Hypofractionated stereotactic radiotherapy for oligometastatic patients: developing of a response predictive model

Author

Diletto, B., Dinapoli, Nicola, Chiesa, Silvia, Mattiucci, Gian Carlo, Frascino, Vincenzo, Anile, Carmelo, Colosimo, Cesare, Valentini, Vincenzo, Balducci, Mario, Dinapoli N., Chiesa S. (ORCID:0000-0003-0168-3459), Mattiucci G. C. (ORCID:0000-0001-6500-0413), Frascino V., Anile C. (ORCID:0000-0002-0481-9713), Colosimo C. (ORCID:0000-0003-3800-3648), Valentini V. (ORCID:0000-0003-4637-6487), Balducci M. (ORCID:0000-0003-0398-9726), Diletto, B., Dinapoli, Nicola, Chiesa, Silvia, Mattiucci, Gian Carlo, Frascino, Vincenzo, Anile, Carmelo, Colosimo, Cesare, Valentini, Vincenzo, Balducci, Mario, Dinapoli N., Chiesa S. (ORCID:0000-0003-0168-3459), Mattiucci G. C. (ORCID:0000-0001-6500-0413), Frascino V., Anile C. (ORCID:0000-0002-0481-9713), Colosimo C. (ORCID:0000-0003-3800-3648), Valentini V. (ORCID:0000-0003-4637-6487), and Balducci M. (ORCID:0000-0003-0398-9726)

Abstract

Objectives: Treatment of oligometastatic patients is a current challenge in radiation oncology. Aim of this study is to define a dose–response relationship for hypofractionated radiotherapy of oligometastases. Methods: Retrospective analysis of metastases treated by hypofractionated stereotactic radiotherapy was performed. Delivered dose was calculated both as biological effective dose (BED10), and as ratio between BED10 and the logarithm of metastasis volume (BED10 logVolume Ratio, BVR). Two dose–response models were defined by logistic regression. The fitted outcome was the Metastases Complete Response (MCR). Performances of the models were assessed by area under the receiver operating curve (AUC) and by bootstrap calibration of original data. BED10 and BVR impact on survival outcomes has been evaluated. Results: Fifty-three patients with 79 metastases were analyzed. AUC and calibration of BVR-based logistic model showed better accuracy in predicting MCR with respect to BED10-based model. No significant difference between the two ROCs was observed (De Long test p value > 0.05), but significant discordance in calibration resulted in the BED10 model (p value < 0.05 in Hosmer–Lemeshow Goodness of fit test). BVR returned also better results in multivariate analyses for survival outcomes. Conclusions: The ratio between BED10 and the logarithm of metastasis volume (BVR), as a corrective factor for fitting the probability of metastases response to stereotactic radiotherapy, could be a tool for evaluating and prescribing treatments for oligometastatic disease. BVR can be useful for producing more reliable survival statistics too.

Published
2018

12. Final results of the second prospective AIEOP protocol for pediatric intracranial ependymoma

Author

Massimino, M, Miceli, R, Giangaspero, F, Boschetti, L, Modena, P, Antonelli, M, Ferroli, P, Bertin, D, Pecori, E, Valentini, L, Biassoni, V, Garrè, M, Schiavello, E, Sardi, I, Cama, A, Viscardi, E, Scarzello, G, Scoccianti, S, Mascarin, M, Quaglietta, L, Cinalli, G, Diletto, B, Genitori, L, Peretta, P, Mussano, A, Buccoliero, A, Calareso, G, Barra, S, Mastronuzzi, A, Giussani, C, Marras, C, Balter, R, Bertolini, P, Giombelli, E, La Spina, M, Buttarelli, F, Pollo, B, Gandola, L, GIUSSANI, CARLO GIORGIO, Gandola, L., Massimino, M, Miceli, R, Giangaspero, F, Boschetti, L, Modena, P, Antonelli, M, Ferroli, P, Bertin, D, Pecori, E, Valentini, L, Biassoni, V, Garrè, M, Schiavello, E, Sardi, I, Cama, A, Viscardi, E, Scarzello, G, Scoccianti, S, Mascarin, M, Quaglietta, L, Cinalli, G, Diletto, B, Genitori, L, Peretta, P, Mussano, A, Buccoliero, A, Calareso, G, Barra, S, Mastronuzzi, A, Giussani, C, Marras, C, Balter, R, Bertolini, P, Giombelli, E, La Spina, M, Buttarelli, F, Pollo, B, Gandola, L, GIUSSANI, CARLO GIORGIO, and Gandola, L.

Abstract

Background This prospective study stratified patients by surgical resection (complete = NED vs incomplete = ED) and centrally reviewed histology (World Health Organization [WHO] grade II vs III). Methods WHO grade II/NED patients received focal radiotherapy (RT) up to 59.4 Gy with 1.8 Gy/day. Grade III/NED received 4 courses of VEC (vincristine, etoposide, cyclophosphamide) after RT. ED patients received 1-4 VEC courses, second-look surgery, and 59.4 Gy followed by an 8-Gy boost in 2 fractions on still measurable residue. NED children aged 1-3 years with grade II tumors could receive 6 VEC courses alone. Results From January 2002 to December 2014, one hundred sixty consecutive children entered the protocol (median age, 4.9 y; males, 100). Follow-up was a median of 67 months. An infratentorial origin was identified in 110 cases. After surgery, 110 patients were NED, and 84 had grade III disease. Multiple resections were performed in 46/160 children (28.8%). A boost was given to 24/40 ED patients achieving progression-free survival (PFS) and overall survival (OS) rates of 58.1% and 68.7%, respectively, in this poor prognosis subgroup. For the whole series, 5-year PFS and OS rates were 65.4% and 81.1%, with no toxic deaths. On multivariable analysis, NED status and grade II were favorable for OS, and for PFS grade II remained favorable. Conclusions In a multicenter collaboration, this trial accrued the highest number of patients published so far, and results are comparable to the best single-institution series. The RT boost, when feasible, seemed effective in improving prognosis. Even after multiple procedures, complete resection confirmed its prognostic strength, along with tumor grade. Biological parameters emerging in this series will be the object of future correlatives and reports.

Published
2016

16. Severe Cholestatic Hepatitis due to Temozolomide: An Adverse Drug Effect to Keep in Mind. Case Report and Review of Literature

Author

Grieco, A, Tafuri, Ma, Biolato, Marco, Diletto, B, Di Napoli, N, Balducci, N, Vecchio, Fabio Maria, Miele, Luca, Biolato, M, Vecchio, FM (ORCID:0000-0002-9197-2264), Miele, L (ORCID:0000-0003-3464-0068), Grieco, A, Tafuri, Ma, Biolato, Marco, Diletto, B, Di Napoli, N, Balducci, N, Vecchio, Fabio Maria, Miele, Luca, Biolato, M, Vecchio, FM (ORCID:0000-0002-9197-2264), and Miele, L (ORCID:0000-0003-3464-0068)

Abstract

Temozolomide is the current standard of therapy for postoperative patients with glioblastoma starting adjuvant radiotherapy. Hematologic adverse events are the most frequent side effects of temozolomide, while liver toxicity has been reported only in the post-marketing period.Here we report a case of severe temozolomide-induced liver injury during concurrent radiotherapy treatment, at a dose level of 75 mg/m(2).The aim of this case report is to focus on the problems of temozolomide-induced hepatotoxicity. In conclusion, a close monitoring of liver function tests is recommended during treatment with temozolomide.

Published
2015

17. OC-0310: Hypofractionated radiotherapy (RT) boost for children with Ependymoma and a measurable residue after surgery

Author

Gandola, L., primary, Pecori, E., additional, Scarzello, G., additional, Barra, S., additional, Mascarin, M., additional, Scoccianti, S., additional, Diletto, B., additional, Mussano, A., additional, Garré, M.L., additional, Sardi, I., additional, Meroni, S., additional, Biassoni, V., additional, Pignoli, E., additional, Giangaspero, F., additional, and Massimino, M., additional

Published
2015
Full Text
View/download PDF

24. Low-dose fractionated radiotherapy and concomitant chemotherapy for recurrent or progressive glioblastoma : Final report of a pilot study

Author

Balducci, M, Diletto, B, Chiesa, S, D'Agostino, Gr, Gambacorta, Ma, Ferro, M, Colosimo, Cesare, Maira, G, Anile, Carmelo, Valentini, V., Colosimo, Cesare (ORCID:0000-0003-3800-3648), Anile, Carmelo (ORCID:0000-0002-0481-9713), Balducci, M, Diletto, B, Chiesa, S, D'Agostino, Gr, Gambacorta, Ma, Ferro, M, Colosimo, Cesare, Maira, G, Anile, Carmelo, Valentini, V., Colosimo, Cesare (ORCID:0000-0003-3800-3648), and Anile, Carmelo (ORCID:0000-0002-0481-9713)

Abstract

Evaluated in this study were the feasibility and the efficacy of concurrent low dose fractionated radiotherapy (LD-FRT) and chemotherapy as palliative treatment for recurrent/progressive glioblastoma multiforme (GBM).

Published
2014

42. Low-dose fractionated radiotherapy and concomitant chemotherapy in glioblastoma multiforme with poor prognosis: a feasibility study

Author

Balducci, M., primary, Chiesa, S., additional, Diletto, B., additional, D'Agostino, G. R., additional, Mangiola, A., additional, Manfrida, S., additional, Mantini, G., additional, Albanese, A., additional, Fiorentino, A., additional, Frascino, V., additional, De Bari, B., additional, Micciche', F., additional, De Rose, F., additional, Morganti, A. G., additional, Anile, C., additional, and Valentini, V., additional

Published
2011
Full Text
View/download PDF

45. Chemotherapy plus concomitant low-dose fractionated radiotherapy as second-line treatment for recurrent or progressive glioblastoma after temozolomide-based chemoradiation: A pilot study.

Author

D'Agostino, G. R., primary, Diletto, B., additional, Manfrida, S., additional, Mangiola, A., additional, Chiesa, S., additional, De Filippo, L., additional, Frascino, V., additional, Micciche', F., additional, Anile, C., additional, and Balducci, M., additional

Published
2011
Full Text
View/download PDF

46. 845 poster LOW DOSE FRACTIONATED RADIOTHERAPY AND TEMOZOLOMIDE IN NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME: PRELIMINARY RESULTS OF A PILOT STUDY

Author

Chiesa, S., primary, Diletto, B., additional, D'Agostino, G.R., additional, Manfrida, S., additional, Mantini, G., additional, de Filippo, L., additional, Frascino, V., additional, Fersino, S., additional, Mangiola, A., additional, Anile, C., additional, Valentini, V., additional, and Balducci, M., additional

Published
2011
Full Text
View/download PDF

47. 846 poster LOW-DOSE FRACTIONATED RADIOTHERAPY PLUS CHEMOTHERAPY IN PATIENTS AFFECTED BY GLIOBLASTOMA MULTIFORME IN FIRST RECURRENT OR PROGRESSIVE DISEASE: INTERIM ANALYSIS.

Author

D'Agostino, G.R., primary, Chiesa, S., additional, Manfrida, S., additional, Diletto, B., additional, Mantini, G., additional, Frascino, V., additional, Miccichè, F., additional, Autorino, R., additional, Valentini, V., additional, de Rose, F., additional, Anile, C., additional, and Balducci, M., additional

Published
2011
Full Text
View/download PDF

49. 294 oral RUTHENIUM PLAQUE BRACHYTHERAPY FOR UVEAL MELANOMA

Author

Smaniotto, D., primary, Diletto, B., additional, Fersino, S., additional, Azario, L., additional, Sammarco, M.G., additional, Pagliara, M., additional, Caputo, M.C., additional, Scupola, A., additional, D'Amico, G., additional, Tagliaferri, L., additional, Luzi, S., additional, Balestrazzi, E., additional, Blasi, M.A., additional, and Cellini, N., additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results